Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

• Status: NOT_YET_RECRUITING
• Trial end date: 2030-12-31

Summary

The purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.

• Phase: PHASE2

Details

• Lead Sponsor: Canadian Cancer Trials Group
• Collaborator: BeOne Medicines
• Treatments: Immunotherapy, Adoptive; zanubrutinib